DNA methylation and expression of the folate transporter genes in colorectal cancer

Tumor Biology

Volumn 36, Issue 7, 2015, Pages 5581-5590

  Farkas, Sanja A ^a   Befekadu, Rahel ^a   Hahn Strömberg, Victoria ^a   Nilsson, Torbjörn K ^b  

^a Örebro University   (Sweden)

^b UMEÅ UNIVERSITY   (Sweden)

Author keywords

CpG; CRC; Immunohistochemistry; Reduced folate carrier; T DMR

Indexed keywords

DNA; FOLATE RECEPTOR 1; PROTON COUPLED FOLATE TRANSPORTER; REDUCED FOLATE CARRIER; REDUCED FOLATE CARRIER 1; UNCLASSIFIED DRUG; FOLIC ACID; FOLR1 PROTEIN, HUMAN; REPLICATION FACTOR C; RFC1 PROTEIN, HUMAN; SLC46A1 PROTEIN, HUMAN;

ARTICLE; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER STAGING; CANCER TISSUE; CLINICAL ARTICLE; COLON MUCOSA; COLORECTAL CANCER; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; EPIGENETICS; FOLR1 GENE; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PCFT GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PYROSEQUENCING; RECTUM MUCOSA; RFC1 GENE; TISSUE SPECIFICITY; TUMOR LOCALIZATION; BIOSYNTHESIS; COLORECTAL TUMOR; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; PATHOLOGY; PROMOTER REGION;

COLORECTAL NEOPLASMS; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; FOLATE RECEPTOR 1; FOLIC ACID; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM STAGING; PROMOTER REGIONS, GENETIC; PROTON-COUPLED FOLATE TRANSPORTER; REPLICATION PROTEIN C;

EID: 84938198358     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3228-2     Document Type: Article

References (39)

1. Jemal A et al. Global Cancer Statistics. CA Cancer J Clin. 2011;61(2):69–90.
2. Al-Sohaily S et al. Molecular pathways in colorectal cancer. J Gastroenterol Hepatol. 2012;27(9):1423–31.
3. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology. 2007;50(1):113–30.
4. Stover PJ, Field MS. Trafficking of intracellular folates. Adv Nutr (Bethesda, Md). 2011;2(4):325–31.
5. Liu M et al. Structure and regulation of the murine reduced folate carrier gene: identification of four noncoding exons and promoters and regulation by dietary folates. J Biol Chem. 2005;280(7):5588–97.
6. Qiu A et al. Rodent intestinal folate transporters (SLC46A1): secondary structure, functional properties, and response to dietary folate restriction. Am J Physiol Cell Physiol. 2007;293(5):C1669–78.
7. Shia J et al. Immunohistochemical expression of folate receptor alpha in colorectal carcinoma: patterns and biological significance. Hum Pathol. 2008;39(4):498–505.
8. Kelemen LE. The role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander? Int J Cancer. 2006;119(2):243–50.
9. Teng L, Xie J, Lee RJ. Clinical translation of folate receptor-targeted therapeutics. Expert Opin Drug Deliv. 2012;9(8):901–8.
10. Ly A et al. Folate and DNA methylation. Antioxid Redox Signal. 2012;17(2):302–26.
11. Kim YI. Nutritional epigenetics: impact of folate deficiency on DNA methylation and colon cancer susceptibility. J Nutr. 2005;135(11):2703–9.
12. Duthie SJ et al. Impact of folate deficiency on DNA stability. J Nutr. 2002;132(8):2444S–9S.
13. Farkas SA et al. Epigenetic alterations in folate transport genes in placental tissue from fetuses with neural tube defects and in leukocytes from subjects with hyperhomocysteinemia. Epigenetics. 2013;8(3):303–16.
14. Tiernan JP et al. Carcinoembryonic antigen is the preferred biomarker for in vivo colorectal cancer targeting. Br J Cancer. 2013;108(3):662–7.
15. Parker N et al. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem. 2005;338(2):284–93.
16. Shia, J., et al., Immunohistochemical expression of folate receptor a in colorectal carcinoma: patterns and biological significance. Hum Pathol, 2008;39(4).
17. Whetstine JR, Flatley RM, Matherly LH. The human reduced folate carrier gene is ubiquitously and differentially expressed in normal human tissues: identification of seven non-coding exons and characterization of a novel promoter. Biochem J. 2002;367:629–40.
18. Nunez MI et al. High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [corrected] mutation. J Thorac Oncol. 2012;7(5):833–40.
19. Iwakiri S et al. Expression status of folate receptor alpha is significantly correlated with prognosis in non-small-cell lung cancers. Ann Surg Oncol. 2008;15(3):889–99.
20. Chen YL et al. Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response. Mol Oncol. 2012;6(3):360–9.
21. Brown Jones M et al. Rationale for folate receptor alpha targeted therapy in "high risk" endometrial carcinomas. Int J Cancer. 2008;123(7):1699–703.
22. Qiu A et al. Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption. Cell. 2006;127(5):917–28.
23. Luo Y, Yu M, Grady WM. Field cancerization in the colon: a role for aberrant DNA methylation? Gastroenterol Rep (Oxf). 2014;2(1):16–20.
24. Taby R, Issa JP. Cancer epigenetics. CA Cancer J Clin. 2010;60(6):376–92.
25. De Bustos C et al. Tissue-specific variation in DNA methylation levels along human chromosome 1. Epigenetics Chromatin. 2009;2(1):7.
26. Doi A et al. Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat Genet. 2009;41(12):1350–3.
27. Irizarry R et al. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet. 2009;41(2):178–86.
28. Liu MJ et al. Transcriptional regulation of the human reduced folate carrier in childhood acute lymphoblastic leukemia cells. Clin Cancer Res. 2006;12(2):608–16.
29. Rothem L et al. Reduced folate carrier gene silencing in multiple antifolate-resistant tumor cell lines is due to a simultaneous loss of function of multiple transcription factors but not promoter methylation. J Biol Chem. 2004;279(1):374–84.
30. Kastrup IB et al. Genetic and epigenetic alterations of the reduced folate carrier in untreated diffuse large B-cell lymphoma. Eur J Haematol. 2008;80(1):61–6.
31. Worm J et al. Methylation-dependent silencing of the reduced folate carrier gene in inherently methotrexate-resistant human breast cancer cells. J Biol Chem. 2001;276(43):39990–40000.
32. Ferreri AJ et al. Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas. Br J Haematol. 2004;126(5):657–64.
33. Gonen N, Bram EE, Assaraf YG. PCFT/SLC46A1 promoter methylation and restoration of gene expression in human leukemia cells. Biochem Biophys Res Commun. 2008;376(4):787–92.
34. Diop-Bove NK et al. Hypermethylation of the human proton-coupled folate transporter (SLC46A1) minimal trancriptional regulatory region in an antifolate-resistant HeLa cell line. Mol Cancer Ther. 2009;8(8):2424–31.
35. Kulis M et al. Intragenic DNA methylation in transcriptional regulation, normal differentiation and cancer. Biochim Biophys Acta. 2013;1829(11):1161–74.
36. Hsueh CT, Dolnick BJ. Regulation of folate-binding protein gene expression by DNA methylation in methotrexate-resistant KB cells. Biochem Pharmacol. 1994;47(6):1019–27.
37. Lind GE et al. Identification of an epigenetic biomarker panel with high sensitivity and specificity for colorectal cancer and adenomas. Mol Cancer. 2011;10.
38. Wettergren Y et al. p16INK4a gene promoter hypermethylation in mucosa as a prognostic factor for patients with colorectal cancer. Mol Med. 2008;14(7–8):412–21.
39. Kawakami K et al. Low expression of gamma-glutamyl hydrolase mRNA in primary colorectal cancer with the CpG island methylator phenotype. Br J Cancer. 2008;98(9):1555–61.